3. 
Post-treatment (see Table on page 20). Complete evaluation of 
evaluable lesions with physical examination, biopsy, if feasible, and 
appropriate x-rays and/or scans prior to each cell infusion cycle and at 
approximately eight weeks after the end of treatment to evaluate response to 
treatment . 
Western blot analysis of patient serum to determine possible exposure to 
retrovirus envelope proteins will be performed at 7 to 8 weeks after 
treatment . 
4. Criteria for response . Complete response is defined as the 
disappearance of all clinical evidence of disease for at least four weeks. 
Partial response is defined as the 50% or greater decrease of the sum of the 
products of perpendicular diameters of all lesions lasting at least four weeks 
with no increase in existing lesions or appearance of new lesions. Any 
patient having less than a partial response is considered to be non-responsive 
to treatment. 
VI. POTENTIAL SIDE EFFECTS AND REPORTING OF ADVERSE REACTIONS . 
1. Adverse drug reaction reporting will be performed in accord with NCI 
current reporting requirements for Phase I studies as follows: 
Report by telephone to IDB within 24 hours (301-496-7957, Available 24 
hours) . 
a. All life threatening events (Grade 4) which may be due to drug 
administration. 
b. All fatal events. 
c. The first occurrence of any previously unknown clinical 
event (regardless of Grade) . 
Written report to following within 10 working days to: 
Investigational Drug Branch 
P.O. Box 30012 
Bethesda, Maryland 20824 
2 . Da ta will be submitted to CTMS at least once every two weeks. 
The NCI/DCT Case Report of ACES will be used to report to CTMS. All adverse 
[78] 
Recombinant DNA Research, Volume 15 
